Почетна › Дебелина › Пенсилванија
Клинички испитувања за Дебелина во Пенсилванија
48 студии за Дебелина бараат учесници на локации во Пенсилванија.
Градови во Пенсилванија
Официјален текст на студијата (англиски)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Suburban Research Associates, West Chester
- Cardiology Consultants of Philadelphia Yardley, Yardley
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07783802A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Heritage Valley Medical Group, Beaver
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07564414A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- UPMC Child Hosp-Pittsburgh, Pittsburgh
Се регрутираФаза 3
Возраст од 8 до 18 · Сите полови · Ажурирано 30.9.2026 · NCT07253285A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Geisinger Clinic, Danville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07668414A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Smithfield
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07776509Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
- Penn State Milton S. Hershey Medical Center, Hershey
Се регрутираРана фаза 1
Возраст од 18 до 65 · Сите полови · Ажурирано 24.9.2026 · NCT06482853Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Се регрутираФаза 3
Возраст од 6 до 17 · Сите полови · Ажурирано 24.9.2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937086AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT07339423A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
- Preferred Primary Care Physicians, Uniontown
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Scottdale
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Heritage Valley Multispecialty Group Inc, Beaver
- Capital Area Research LLC, Camp Hill
- Abington Medical Specialists, Horsham
Се регрутираФаза 3
Возраст од 45 до 99 · Сите полови · Ажурирано 22.9.2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Preferred Primary Care Physicians, Uniontown
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Keystone Clinical Studies, Plymouth Meeting
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Philadelphia
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Philadelphia
- AURORA-2 Clinical Site, Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Abington Medical Specialists, Horsham
- University of Pittsburgh Medical Center, Pittsburgh
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 16.9.2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- VA Pittsburgh Healthcare System, Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Frontier Clinical Research, LLC, Scottdale
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 14.9.2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Suburban Research Associates - West Chester Office, West Chester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351045AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT07571005A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Philadelphia
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст од 18 до 79 · Сите полови · Ажурирано 11.9.2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT07770841AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT07571109A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dermatology Associates of Plymouth Meeting, Plymouth Meeting
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Capital Area Research LLC, Newport
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Altoona Center for Clinical Research, Duncansville
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 27.8.2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Philadelphia
- Research Site, Smithfield
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
Се регрутираФаза 2
Возраст од 7 до 25 · Сите полови · Ажурирано 19.8.2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Penn State Hlth Holy Spirit Med Ctr, Camp Hill
- Chambersburg Hospital, Chambersburg
- Doylestown Heath cardiology, Doylestown
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Philadelphia
Се регрутираФаза 3
Возраст од 18 до 79 · Сите полови · Ажурирано 10.8.2026 · NCT07654361Fast In-Bed Tracking (FIT) System Lifestyle Intervention is a Clinical Trial of a Bed Scale Device. Overweight Wheelchair Users Will Complete a Weight Loss Program, Half Get Scales at Baseline, Half at Month 6 Those Who Receive the Bed Scales at Baseline Are Expected to Have Increased Weight Loss
- University of Pittsburgh, Bakery Square, Department of Rehabilitation Science and Technology, Pittsburgh
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 29.7.2026 · NCT07141342Pharmacogenetics of Response to GLP1R Agonists
- Amish Research Clinic, Lancaster
Се регрутираФаза 1Добредојдени се здрави волонтери
Возраст од 18 до 89 · Сите полови · Ажурирано 27.7.2026 · NCT05071898A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Altoona Center for Clinical Research, Duncansville
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 22.7.2026 · NCT07477704An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents
- Drexel University, Philadelphia
Се регрутираДобредојдени се здрави волонтери
Возраст од 14 до 19 · Жени · Ажурирано 20.7.2026 · NCT06147973Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study
- Villanova University, Villanova
Се регрутира
Возраст од 18 до 35 · Сите полови · Ажурирано 17.7.2026 · NCT07334470Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Pittsburgh, Pittsburgh
Се регрутира
Возраст од 18 до 45 · Жени · Ажурирано 24.6.2026 · NCT05124808The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication
- Physical Activity Research Center, University of Pittsburgh, Pittsburgh
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 24.6.2026 · NCT07652333Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.